The Company is investigating the health effects of various natural remedies on the health of consumers either alone or in conjunction with other elements.
In focus are various plant based products that are targeted to relieve symptoms such as:
- Chronic inflammation
- High Cholesterol
Initial projects will include Astaxanthin, Spirulina and eventually Cannabinoids.
A cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid receptors in cells that alter neurotransmitter release in the brain. Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially). The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.READ MORE
Cannabidiol (abbreviated as: CBD) is one of at least 113 cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. CBD does not appear to have any psychoactive effects such as those caused by tetrahydrocannabinol (THC). It may have a down regulating impact on disordered thinking and anxiety. Potential uses are the subject of ongoing research.
Pain associated with multiple sclerosis
Nabiximols (USAN, trade name Sativex) is an aerosolized mist for oral administration containing a near 1:1 ratio of CBD and THC. The drug was approved by Canadian authorities in 2005 to alleviate pain associated with multiple sclerosis.
Two systematic review on CBD and addiction reported beneficial effects for alleviating tobacco and cannabis dependence. The anti-addictive properties displayed might be due to CBD’s protective effect on stress and neurotoxicity. Both reviews recommended more research.
Two reviews address research on the theory that CBD alone or in combination with THC may have anti-oxidant and anti-inflammatory activity. Neither cited any human trials.
Anecdotal reports and early studies suggested that CBD may be of value in treating epilepsy, but the quality of the studies was too poor to draw definitive conclusions. A 2014 Cochrane review included four randomized controlled trials, but all were of poor quality. A double-blinded, randomized, placebo-controlled study of CBD oil on treating Dravet syndrome, a rare form of epilepsy that begins in infancy and is difficult to treat, was conducted in 2017 and found that CBD oil significantly reduced the number of seizures with a dosing of 20mg/kg. However, it also caused increased diarrhea, vomiting, fevers, fatigue, abnormal liver function tests (LFTs), and somnolence. The LFTs showed elevated ALT and AST up to three times of normal, but only in the patients also taking valproate. The study already suggests that this might be an interaction of valproate and CBD. The abnormal LFT normalized during the trial in the patients who kept taking CBD.
GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD, under the trade name Epidiolex (containing 99% cannabidiol and less than 0.10% Δ9-THC) as a treatment for Dravet syndrome. Epidiolex was granted fast-track status and orphan drug status in the United States for treatment of Dravet syndrome in July 2015.
The Company is currently building out a hemp-based CBD products development enterprise in Nevada. The operating subsidiary of EVA will be focused on developing and marketing CBD based products for the general consumer and sports focused channels.